AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05154747
Drug: Cabotegravir, Rilpivirine Drug Combination
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cabotegravir LA 600mg as a 3mL IM injection. The product is packaged in a 3mL USP Type I glass vial. Each vial is for single-dose use. CAB LA injectable suspension is to be stored according to the product label at room temperature (\<30oC). CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol3350, mannitol, and water for injection.~Rilpivirine LA 900mg as a 3mL IM injection. Each single-dose vial contains 900mg/3mL rilpivirine. RPV LA injectable suspension should be stored according to the product label refrigerated at 2-8oC and should be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, and water for injection.~Cabotegravir Long-Acting (CAB LA) will be given IM into one buttock, and Rilpivirine Long-Acting (RPV LA) will be given IM into the opposite buttock.
Trial: NCT05154747
Drug: TLD
RxNorm normalized name: Tenofovir, Lamivudine, and Dolutegravir
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dolutegravir 50mg oral with tenofovir disoproxil fumarate (245mg) and lamivudine (300mg) in a fixed dose combination or Dolutegravir 50mg oral with tenofovir alafenamide fumarate (25mg) and lamivudine (300mg) (l/TAF) oral in a fixed dose combination
Trial: NCT05191862
Drug: Cilostazol 100 mg
RxNorm normalized name: cilostazol 100 MG
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
Trial: NCT05574036
Drug: Febuxostat 80 MG Oral Tablet
RxNorm normalized name: FEBUXOSTAT 80 mg ORAL TABLET
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat used as 80 mg oral tablet once daily for 6 months
Trial: NCT05574036
Drug: vit E
RxNorm normalized name: tocopherol (vit E)
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
Trial: NCT06067438
Drug: Amiodarone Hydrochloride
RxNorm normalized name: Amiodarone Hydrochloride
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV and via feeding tube
Trial: NCT05273554
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV
Trial: NCT05273554
Drug: lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO
Trial: NCT05458232
Drug: Tadalafil 5mg
RxNorm normalized name: TADALAFIL 5MG TAB
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will ingest one 5mg tablet of tadalafil each evening for 14 days.
Trial: NCT05575804
Drug: GQ1001+pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity. I.
Trial: NCT05135975
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Enrolled patients will be treated with cabozantinib maleate, tablet formulation, using the recommended Phase 2 dose of 40 mg/m2/day to a maximum of 420 mg/week. Treatment will be administered in 28- day cycles.
Trial: NCT06274333
Drug: Dexmedetomidine 0.5 mic/kg
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg,
Trial: NCT06274333
Drug: Tramadol 1mg/kg
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
Trial: NCT06328062
Drug: Mirogabalin
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Participants will receive 5 mg of mirogabalin, taken as half a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
Trial: NCT06328062
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive 50 mg of pregabalin, taken as a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
Trial: NCT05632783
Drug: Chondroitin Sulfate Sodium
RxNorm normalized name: Chondroitin Sulfate Sodium
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate 800 mg tablets
Trial: NCT05260008
Drug: ATX-101
RxNorm normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATX-101 (bupivacaine) implant, one-time administration into the surgical site
Trial: NCT05120349
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease recurrence, unacceptable toxicity or other discontinuation criteria are met.
Trial: NCT05410145
Drug: D3S-001
RxNorm normalized name: D3S-001
DrugBank: D3S-001 (DB19008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05410145
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous
Trial: NCT05410145
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT05410145
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT05410145
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous
Trial: NCT05410145
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous
Trial: NCT05885685
Drug: Nabilone Oral Capsule
RxNorm normalized name: nabilone Oral Capsule
DrugBank: Nabilone (DB00486)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each oral capsule contains a 0.25 mg dose of nabilone. Participants begin by taking 1 capsule at night then 1 capsule in the morning and 1 at night for the next 2 days. On the 4th day, the dose is doubled. On the 6th day, the dose is doubled again.
Trial: NCT05373004
Drug: Empagliflozin 25 MG
RxNorm normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: It is the experimental drug in this trial. this drug has an approved efficacy in delaying kidney deterioration based on the results of (the EMPA-REG OUTCOME) trial. it is also recommended based on the ADA/EASD 2019 consensus, as the SGLT2 inhibitors are recommended in patients with type 2 diabetes in patients with CKD to prevent the progression of CKD. However, the previous trials where always add it to a patient already on an ACE inhibitor (in most cases). In this trial, it will be compared head to head with the gold standard treatment of CKD which is Enalapril 20 mg (ACE inhibitor).
Trial: NCT04952389
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Twice daily nasal rinses with steroid medication (budesonide)
Trial: NCT05373004
Drug: Enalapril Maleate 20 mg
RxNorm normalized name: enalapril maleate 20 MG
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It is an ACE inhibitor, the active comparator in this trial, and is considered the gold standard for the treatment of diabetic kidney disease.
Trial: NCT06511011
Drug: Modified Suan ZaoRen Tang-TianWang BuXin Dan
RxNorm normalized name: Dan shen suan b
DrugBank: Salvianolic acid B (DB19313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine granules for 6 weeks
Trial: NCT05572229
Drug: Teclistamab
RxNorm normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teclistamab will be administered via a subcutaneous injection (SC)
Trial: NCT05572229
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab will be administered via a subcutaneous injection (SC)
Trial: NCT05572229
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide will be administered orally
Trial: NCT05040178
Drug: Carglumic Acid
RxNorm normalized name: Carglumic Acid
DrugBank: Carglumic acid (DB06775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Current or previous treatment with Carbaglu, the dose of Carbaglu® prescribed will be determined by the investigator for each individual patient.
Trial: NCT05582577
Drug: Intravitreal bevacizumab injection alone
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Group B: Intravitreal injection of Bevacizumab alone
Trial: NCT06673121
Drug: Traditional Chinese Medicine
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
DrugBank: Borneol (DB11288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received treatment with traditional Chinese medicine
Trial: NCT04973228
Drug: Roflumilast Foam
RxNorm normalized name: roflumilast Topical Foam
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast 0.3% foam for topical application
Trial: NCT04973228
Drug: Vehicle Foam
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle foam for topical application
Trial: NCT06671327
Drug: Preemptive Dexmedetomidine injection
RxNorm normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The DEX group was continuously pumped at 1.5 μg /(kg·h) for 15 minutes before induction, and after induction continue infusion 15min.
Trial: NCT06671327
Drug: Sodium Chloride 0.9% Inj
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Placebo group was infused with equal amounts of isochronous normal saline.
Trial: NCT05431582
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by vein over about 30-60 minutes on Day 1 of each cycle
Trial: NCT05431582
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by vein over 30-60 minutes on Day 1 of each cycle.
Trial: NCT04151563
Drug: cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on Specified days
Trial: NCT04151563
Drug: lucitanib
RxNorm normalized name: Lucitanib
DrugBank: Lucitanib (DB11845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on Specified days
Trial: NCT05874219
Drug: Mupirocin 2% ointment
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mm of mupirocin ointment squeezed directly on to their exit sites from a 15 g tube with an outlet diameter of 5 mm
Trial: NCT00308542
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06701513
Drug: Deucravacitinib
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed by treating clinician
Trial: NCT06627244
Drug: Tebentafusp
RxNorm normalized name: Tebentafusp
DrugBank: Tebentafusp (DB15283)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tebentafusp will be administered intravenously to participants at or within 28 days of their first Y-90 TARE procedure. This 28-day period includes the 14- to 28-day Y-90 TARE Recovery Period. For administrative purposes, one cycle of tebentafusp treatment is 28 days in length. Tebentafusp will be administered on a dose escalation schedule for Cycle 1 starting at 20 mcg on Day 1, increasing to 30 mcg on Day 8, and a final dose of 68 mcg on Day 15, which will be administered once per week until unacceptable toxicity develops, disease progression, or withdrawal of consent, whichever occurs first.
Trial: NCT06701526
Drug: Eptinezumab
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solution for infusion
Trial: NCT04998422
Drug: HG381
RxNorm normalized name: Hydrocodone Bitartrate and Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HG381 is available as white to off-white cake or powder for solution for injection at a unit dose strength of 5 mg per vial. HG381 will be administered as IV injection.
Trial: NCT05132738
Drug: Ripretinib treatment
RxNorm normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ripretinib: 4-week (28-day) cycle of oral administration of 150 mg q.d. For patients who completed up to 6 consecutive treatment cycles in a the clinical investigator decided whether to perform the operation or not, the specific time and other matters.~The above medications can be adjusted according to the adverse reactions of subjects according to the protocol at the investigator's discretion. Subjects will continue treatment until disease progression, intolerable toxicity, withdrawal of informed consent, or discontinuation of treatment as judged by the investigator, and the investigator will decide whether to perform early surgery or subsequent treatment regimen.
Trial: NCT05405543
Drug: MYK-224
RxNorm normalized name: MYK-461
DrugBank: Mavacamten (DB14921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT01430429
Drug: NI-0801
RxNorm normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04818450
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 100-300 mg is given to the intervention group
Trial: NCT05795465
Drug: GEn-1124
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05870007
Drug: Atorvastatin 20 Mg Oral Tablet
RxNorm normalized name: atorvastatin 20 mg oral tablet
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg
Trial: NCT05870007
Drug: Sodium Bicarbonate 600 Mg Oral Tablet
RxNorm normalized name: sodium bicarbonate 600 MG Oral Tablet
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate would be titrated up to 1800mg per day according to metabolic acidosis severity during clinical follow-up
Trial: NCT05144295
Drug: Lubiprostone Pill
RxNorm normalized name: lubiprostone Pill
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pills for constipation (Lubiprostone) will be given in a dose range from 24 mcg once daily to 24 mcg twice daily according to the participant weight.
Trial: NCT05144295
Drug: Lactulose Oral Liquid Product
RxNorm normalized name: lactulose Oral Liquid Product
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose  Lactulose, or Duphalac syrup at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day)
Trial: NCT05144295
Drug: Bisacodyl 5 MG
RxNorm normalized name: bisacodyl 5 MG
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bisacodyl tablet (5 mg/tablet) in a dose of 2 tab/day for \< 12 years or 3 tab/day for \> 12 years
Trial: NCT05144295
Drug: Sodium Picosulfate
RxNorm normalized name: Sodium Picosulfate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Picosulfate 0.75% drops in a daily dose of 2.5-20 mg/day
Trial: NCT05700344
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single Group Assignment
Trial: NCT04191278
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will receive a standard 12-week course of varenicline tartrate. Participants will receive 0.5 mg tablets per oral (PO) once daily for days 1-3, 0.5 mg tablets PO twice daily for days 4-7, and 1 mg tablets PO twice daily for days 8-84
Trial: NCT05849740
Drug: Daratumumab and corticosteroid treatment
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab and corticosteroid treatment
Trial: NCT05927142
Drug: Rintatolimod
RxNorm normalized name: Rintatolimod
DrugBank: Rintatolimod (DB16425)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLR-3 agonist, synthetic double-stranded ribonucleic acid (poly I:C12U)
Trial: NCT05717920
Drug: ADX-629 (Open-label)
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADX-629 (250 mg) administered twice daily for 90 days
Trial: NCT05664685
Drug: Optimized bismuth quadruple therapy
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheme that have high dosage of amoxicillin, metronidazole and omeprazole, with bismuth. The rationale of this scheme is that in Chile, amoxicillin resistance is low, clinical metronidazole is low in the doses used and the high doses ob Proton Pump Inhibitor enhanced the antimicrobial drugs
Trial: NCT05664685
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard eradication therapy using omeprazole, clarithromycin and amoxicillin
Trial: NCT06340737
Drug: CD22CART Infusion
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing and Administration Participants will be hospitalized to receive treatment with CD22CART, if not previously hospitalized, and will remain hospitalized for approximately 5 to 7 (±2) days. Patients may be discharged once all AEs have resolved to Grade 1 or better, or at the discretion of the treating physician. Participants may be discharged with non critical and clinically stable or slowly improving toxicities (e.g., renal insufficiency, cytopenias) even if \> Grade 1, if deemed appropriate by the investigator.
Trial: NCT05275972
Drug: Ripasudil
RxNorm normalized name: ripasudil
DrugBank: Ripasudil (DB13165)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Topical Ripasudil 0.4%
Trial: NCT05305560
Drug: Ivermectin Tablets
RxNorm normalized name: Ivermectin Tablets
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily ivermectin tablets intake for 28 days ; 200 mcg/kg on D1 then 100 mcg/kg daily from D2 to D28.
Trial: NCT04060628
Drug: NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05032833
Drug: 5-MeO-DMT
RxNorm normalized name: 5-MeO-DMT
DrugBank: 5-methoxy-N,N-dimethyltryptamine (DB14010)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 5-MeO-DMT will be administered intranasally
Trial: NCT05668013
Drug: TEV-48574 Dose Regiment B
RxNorm normalized name: Immunoglobulin G1 [de-449-lysine], anti-(human tumor necrosis factor superfamily protein TNFSF15) (human monoclonal TEV-48574 γ1-chain), disulfide with human monoclonal TEV-48574 λ-chain, dimer
DrugBank: Duvakitug (DB19444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (sc) administration using a commercial sc infusion system
Trial: NCT00002191
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04884035
Drug: CC-220
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
Trial: NCT04884035
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles
Trial: NCT04884035
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
Trial: NCT04884035
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
Trial: NCT04884035
Drug: CC-99282
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
Trial: NCT04884035
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles